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ABSTRACT 
	  
Objective: The objective of this selective EBM review is to determine whether or not is 
photodynamic therapy with topical 5-aminolaevulinic acid effective for the treatment of adults 
with recalcitrant hand and foot warts. 
 
Study Design: Systemic review of 3 English language primary studies, published between 1999-
2007. 
 
Data Sources: Two randomized controlled trials (RCTs) and one prospective, single-arm, phase 
II study published on/after 1999 comparing treatment of recalcitrant hand and foot warts before 
and after use of photodynamic therapy with topical 5-ALA were obtained using PubMed.  
 
Outcomes Measured: Incidence of disappearance of recalcitrant hand and foot warts was the 
primary outcome measured, measured by Wilcoxon rank-sum test, Chi2 test, 2 way ANOVA, 
measured by a ruler, Fischer’s exact test for two group comparison, and Cox proportional-
Hazards.  
 
Results: Pain, skin pigmentation change, and phototoxic reactions were reported adverse events 
or side effects in some of the studies. Stender, Lock-Anderson and co-authors showed a 
statistically significant reduction in the frequency of warts, with a NNT of 2. Stender, Na and co-
authors also showed a statistically significant reduction, with a NNT of 8.  In a prospective study 
by Wang and co-authors 42% of patients showed complete remission of their recalcitrant hand 
and foot warts.  
 
Conclusion: There was a significant reduction in the number of recalcitrant hand and foots warts 
achieved versus previously proposed methods for treatment. There was a statistically significant 
reduction in the recalcitrant hand and foot warts in all 3 studies, with almost half of the patients 
showing complete remission in Wang and co-authors study and low NNT of 2 and 8 by Stender, 
Lock-Anderson and co-authors and Stender, Na and co-authors respectively.  To start making 
this more of a used modality for treatment, future larger studies with more patients with 
recalcitrant hand and foot warts are needed to evaluate the efficiency of photodynamic therapy 
with topical 5-ALA. 
 
Key words: recalcitrant hand/foot warts, Photodynamic therapy, topical 5-aminolaevulinic acid 
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INTRODUCTION  
Hand and foot warts (verrucae) are small, usually tender skin growths caused most 
commonly by HPV type 1 that are flattened by pressure and surrounded by cornified epithelium.1  
Hand and foot warts most commonly affect children and adolescents, but can be the most 
bothersome in adults. This is because in children these warts tend to resolve without treatment 
over several months to years, but in adults they tend to persist longer usually requiring patients to 
seek out treatment.  While there is no one exact criteria for recalcitrant warts, they are usually 
considered those that persist after several months of standard treatment. 1  In the Stender, Na and 
co-authors study recalcitrant warts were defined as warts that persisted after 3 months of any 
treatment.2  In the Stender, Lock-Anderson and co-authors recalcitrant warts were defined as 
warts that persisted after an average of 3 years with a variety of treatment.  In the Wang and co-
authors study recalcitrant warts were defined as warts that persisted after 4 sessions of 
cryotherapy.4  Warts are the most common viral infection of the skin, affecting 7-10% of the 
general population.5  Hand and foot warts cause cosmetic, social and functional problems to the 
patient.2  While there is no direct estimate of the cost of warts in the United States, it is estimated 
in the United Kingdom that the annual cost is $40 million.  2 million people in the United 
Kingdom visit their healthcare provider each year with the diagnosis of warts.6 
 Warts are usually skin colored and when palpated are rough, but can be flat and smooth. 
Symptoms of hand and foot warts vary with some patients being completely asymptomatic.  Foot 
warts are more likely to be painful and patients describe feeling a “pebble” in their shoe.  Most 
foot warts do not stick up above the surface and have a black dot.  This is due to the pressure it is 
under when ambulating, pushing them back into the skin.  Mosaic warts are plaques of clustered 
hand or foot warts, which are very difficult to treat.7 
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There are over 100 different HPV types and while some are more prevalent to cause hand 
and foot warts, any of the 100 types can result in these types of warts. Human Papilloma Virus 
(HPV) infects the epithelial tissues of the skin and mucus membranes. The virus replicates in 
differentiated epithelial cells in the upper layer of the epidermis yet the virus can be found in the 
basal layer as well.  This causes excessive growth of cells with the clinical manifestation of the 
virus being the verrucae.  Dissemination systemically of the virus does not occur.9  Infection by 
HPV occurs through skin-to-skin contact or Koebner phenomenon; which is an isomorphic 
response that occurs at sites of trauma, predisposing the patient to inoculation of the virus.  
Although the exact incubation period is unknown, it is believed that it ranges from 1-6 months, 
with a latency period of up to a year or more.8 
There is no exact indication for treatment of plantar and palmar warts and no cure-all 
treatment is available.  Treatment is individually based and should be considered for cosmetic 
reasons, poor location, or when painful.  Currently used methods for treatment are but not limited 
to topical irritants such as: salicylic acid, bichloracetic acid, and trichloroacetic acid.  Destructive 
methods such as cryosurgery and topical and intra-lesional immunotherapy (squaric acid dibutyl 
ester and Candida allergen).2,7   
The treatment options mentioned above all play a role in treating recalcitrant hand and 
foot warts, however there is not one cure that will work for every patient.  Trying to find one 
treatment that is right for the patient can be time consuming for both the practitioner and patient.  
Using photodynamic therapy with topical 5-aminolaevulinic acid is an effective treatment for 
recalcitrant hand and foot warts. 
OBJECTIVE  
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The objective of this selective EBM review is to determine whether or not is 
photodynamic therapy with topical 5-aminolaevulinic acid effective for the treatment of adults 
with recalcitrant hand and foot warts. 
METHODS 
The criteria used for the selection of the 3 studies included healthy, except for the 
recalcitrant warts, men and women over the age of 18 with recalcitrant hand and foot warts. 
Interventions included photodynamic therapy with topical 5-aminolaevulinic acid.  Some 
variations did exist between the 3 studies. 20% ASA cream and photodynamic therapy (PDT) 
was compared to placebo cream with PDT in one RCT.2   In another RCT, ALA and PDT was 
compared to cryotherapy with liquid nitrogen as a spray.3  In the prospective study there was no 
comparison group.4  The outcomes measured in the 3 studies included the incidence of 
disappearance of recalcitrant hand and foot warts. 
 The types of studies included are 2 randomized controlled trials and one prospective, 
single-arm, phase II study.  Stender, Lock-Anderson and co-authors study was not blinded after 
4-6 weeks.3  All articles were published in English in peer reviewed journals.  Data was collected 
using PubMed from 1999-2007.  Key words used included “recalcitrant hand/foot warts”, 
“photodynamic therapy” and “topical 5-aminolaevulinic acid”.	  	  Articles were selected based on 
if they were relevant to my clinical question and if the outcomes mattered to the patients (Patient 
Oriented Evidence that Matters, POEMs).	  	  Inclusion criteria included studies that were either 
RCTs or clinical trials published on/after 1999, additional criteria in Table 1.	  	  Exclusion criteria 
included less than 18 years old. The statistics used to evaluate patient outcomes included RBI, 
ABI, NNT, and p value.  The demographics and characteristics of the included studies are 
displayed in table 1. 
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Table 1: Demographics and Characteristics of included studies  
 
Study Type # Pts Age (yrs.) Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Stender 
(2000) 
Double 
blind 
RCT 
45 
(232 
warts) 
20-84 
(mean=37) 
Consecutive patients with 
recalcitrant (treatment in 
vain by any method for 
more than 3 months) foot 
and hand warts referred to 
the outpatient clinic of the 
Department of 
Dermatology, Bispegjerg 
University Hospital, 
Denmark 
 
Lack of informed 
consent, 
immunosuppressi
ve therapy, other 
reasons for 
immunosuppressi
on, pregnancy, 
breast-feeding, 
and age below 18  
 
6 
warts  
20% ALA 
cream with 
PDT  
 
Wang 
(2007) 
Prospect
ive, 
single-
arm, 
phase II 
study 
 
12 18-70 
(mean=32.8) 
Adult (at least 18 years of 
age) patients from 
outpatient dermatology 
clinics with recalcitrant 
viral warts (defined as 
warts that persisted 
despite four sessions of 
cryotherapy) were 
included.  
 
Pregnancy, 
breast-feeding, 
age less than 18, 
immunosuppressi
on, and a history 
of 
photosensitivity 
or collagen 
vascular disease 
0 5-
aminolevulin
ic acid with 
PDT (red 
light source 
Waldmann 
PDT1200; 
wavelength, 
590-700 nm) 
 
Stender 
(1999) 
RCT 
 
30 
(250 
warts) 
22-74 Referred to the 
Department of 
Dermatology at the 
National University 
Hospital, in Copenhagen 
in late autumn 1995 and in 
the spring 1996. Patients 
had a variety of long-
standing (average 3 years) 
and recalcitrant warts and 
had been treated with a 
variety of modalities such 
as: cryotherapy, caustic 
agents, superficial X-rays, 
excision, curettage and 
laser treatments. 
 
None 2 ALA-PDT 
groups were 
irradiated 
with white 
light applied 
three times 
within 10 
days (W3) 
(Kindermann
, fluence rate 
22m W/cm2 
in 30 min) 
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OUTCOMES MEASURED 
All of the outcomes measured were POEMs related to treating recalcitrant hand and foot 
warts.  In the study by Stender, Lock-Anderson and co-authors the outcomes were measured by 
wart diameter.  This was accomplished by measuring with a ruler and Fischer’s exact test for two 
group comparison.3 
In the study by Stender, Na and co-authors the outcomes were measured by change in 
wart area.  This was accomplished by using Wilcoxon rank-sum test.  Number of vanishing warts 
was measured by Chi2 test. Change in relative area of warts that persisted was measured by 2 
way ANOVA.  Duration of warts before vs. at entry was measured by Cox proportional-Hazards. 
Pain intensity was measured by Mann-Whitney test immediately following PDT and 24 hours 
later.2 
In the study by Wang and co-authors the outcomes were measured for statistical analysis  
using Leming’s single stage, one-sample, multiple testing procedure.  Pain intensity was 
measured by using a five-point scale for pain.4  
RESULTS  
 Three studies compared the use of photodynamic therapy with topical 5-aminolaevulinic 
acid to treat adults age 18 years and older with recalcitrant hand and foot warts.  One was a 
randomized control trial: pilot study3, one was a randomized control trial (double-blind, placebo-
controlled)2, and one was a prospective, single-arm, phase II study4.  Pain and transient skin 
pigmentation change was reported in 2 of the studies with 1 study reporting temporary erythema.  
 Stender, Lock-Anderson, and co-authors studied 30 patients with 250 recalcitrant hand 
and foot warts.  No patients were excluded from the study.  W3 had 73 warts and was the 
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experimental and cryotherapy with liquid nitrogen as a spray had 50 warts.  The participants 
warts in the experimental were given 20% ALA to the wart and 1 cm surrounding the wart and 
then occluded with Tegaderm that was removed 5 hours later. The warts were then irradiated 
with W3 at a distance of 15 cm from the wart, with a total dose of 40 J/cm2.  In the control group 
the warts were frozen for 10 seconds from the time the wart turned white, then allowed to thaw, 
and then the process repeated. Cryotherapy was repeated for a maximum of 4 times within 2 
months.  Wart remission in W3 vs. cryotherapy was significant (p=<.01).  NNT was 2 which 
means for every 2 warts that were treated with W3 and 5-ALA 1 more person was cured than 
with the control treatment.  This is a small value given the study.	  	  Adverse events were mild to 
strong burning and itching in the first few minutes following light exposure which was followed 
by pain.3 
Table 2. Analysis of Outcomes and Numbers Needed to Treat in Patients Using 
Photodynamic Therapy with Topical 5-ALA for Treatment of Recalcitrant Hand and Foot 
Warts by Stender, Lock-Anderson, et. al.  
Study Patients 
(warts) 
CER EER RBI ABI NNT 
Stender, 
Lock-
Anderson 
30 (250 
warts) 
20% 73% 265% 53% 2 
 
Stender, Na, and co-authors studied 45 patients with 232 recalcitrant hand and foot warts.  
Participants were excluded from the study for lack of informed consent, immunosuppressive 
therapy, other reasons for immunosuppression, pregnancy, breast-feeding, and age below 18. 117 
warts were assigned to the ALA-PDT and 115 warts to placebo-PDT for 18 weeks.  All warts 
had the horny layer pared with a scalpel by a dermatologist to visual blood vessels and then the 
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warts received occlusive hydrocolloid dressings with the experimental group receiving 20% 
ALA cream and the control group placebo cream that visually matched and smelled the same.    
4 hours later all warts were irradiated with a red light source ranging in wavelength from 590 nm 
to 700 nm.  Warts were exposed to a fluence rate of 50 mW/cm2.  The ALA-PDT and placebo-
PDT were repeated after 1 and 2 weeks.  If warts still persisted at week 7, ALA-PDT or placebo-
PDT were reapplied 3 times 1 week apart.  Follow-up was at week 18 after the 6th treatment.  
The participants were told to pare their warts with a scalpel 2 times a week and then apply a 
kertolytic (Verucid) locally throughout the entire study.  Warts were photographed and measured 
with a ruler by a Dermatologist unaware of the treatments the participants in the study received.  
The longest and widest part of the wart was recorded.  On week 18, in the ALA-PDT group 64 
warts (56%) vanished while only 47 (42%) vanished in the placebo-PDT.  The number of 
vanished warts was significantly higher, p=0.033, in the ALA-PDT than the placebo-PDT at 
week 18.  The change of wart area on week 18 compared to the start of the study decreased 
significantly in the ALA-PDT versus the placebo-PDT (29%, p=.008).  The CI is very narrow in 
the ALA-PDT versus placebo PDT (95% CI=-18.1 (-3.6, -32.6)).  NNT was 8 which is very 
small for the magnitude of the study (see table 3).  The only event reported was pain and a 
transient hyperpigmentation after removal of warts on the dorsum of hand.  Patients were asked 
to report the level of pain immediately after PDT and then again 24 hours after treatment.  The 
pain was significantly higher in the ALA-PDT versus placebo-PDT.2  
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Table 3. Analysis of Outcomes and Numbers Needed to Treat in Patients Using 
Photodynamic Therapy with Topical 5-ALA for Treatment of Recalcitrant Hand and Foot 
Warts by Stender, Na, et. al.  
Study Patients 
(warts) 
CER EER RBI ABI NNT 
Stender, Na 45 (232 
warts) 
42% 56% 33% 14% 8 
 
 In a prospective study by Wang and co-authors 12 patients with recalcitrant hand and foot 
warts were studied and if patients had more than 1 wart one was chosen for PDT while the other 
was given cryotherapy.  Patients who were pregnant, breast-feeding, age less than 18, 
immunosuppression, and a history of photosensitivity or collagen vascular disease were excluded 
from the study.  The viral warts that were selected for treatment were pared with a scalpel until 
blood vessels were visualized.  20% 5-ALA cream was applied to the wart plus a .5 cm around 
the wart.  Tegaderm was applied for 4 hours and then the warts were irradiated with a red light 
source ranging in wavelength from 590 to 700 nm at an irradiance of 50 mW/cm2 for 20 minutes.  
The total dose was 50 J/cm2.  The same evaluator saw the patients every 2 weeks and if 
necessary the PDT was repeated for a maximum of 4 times.  Photographs were taken at entry and 
then every 2 weeks for 8 weeks.  42% of patients  (5 patients) achieved complete remission 
(p=0.34). The P is >.05, which does question the validity of the study.  Pain peaked at 24 hours 
and lasted for 48 hours with most patients rating the pain only a 1/5 and no patients asked to 
discontinue treatment because of pain.4 
DISCUSSION  
 Recalcitrant hand and foot warts are a common problem that many patients are seeking 
treatment for from practitioners.  While there are various methods for treatment such as but not 
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limited to cryotherapy, excision and caustic agents, a patient can still be left with a recalcitrant 
wart.7  Therefore, photodynamic therapy with 5-ALA is necessary and may be the key for the 
treatment of these warts. 
 However, there are various problems to this proposed therapy.  One problem faced with 
this treatment is the insurance coverage.  While insurance companies do cover the use of PDT 
with 5-ALA for the treatment of other skin conditions such as: cutaneous lesions of Bowen’s 
disease, basal cell carcinoma and refractory actinic keratosis.  Unfortunately insurance 
companies such as Aetna and Cigna consider this an experimental treatment for warts and will 
not cover it.  So patients end up paying out of pocket per treatment, which ends up being very 
costly because warts require numerous treatments before a cure is reached, which is also very 
time consuming for the patient.10,11  Also, FDA does approve the use of photodynamic therapy 
with 5-ALA, but it is not an approved treatment for warts.12   
 There are contraindications for the use of this treatment.  Some contraindications are 
cutaneous photosensitivity, porphyria and allergies to ALA.  It is also not known if ALA is 
excreted through breast milk, so caution needs to be taken when prescribing this to a woman who 
is breastfeeding.  After the application of ALA, the skin has some photosensitivity.  The patient 
should be warned to avoid sunlight or any bright lights.  This can be very tedious to the patient 
due to the topical application of ALA not just being a one-time use.  ALA is considered 
pregnancy category C.13,14 
 There are limitations that exist when obtaining evidence of the effectiveness of 5-ALA 
and PDT in the treatment of recalcitrant hand and foot warts.  The following are limitations that 
all 3 studies share.  Each of the studies started treatment with a keratolytic and curettage before 
applying the 5-ALA and then using photodynamic therapy.  Because of this, there is no way to 
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know if the high response rates are skewed due to the keratolyic and curettage, making 5-ALA 
and PDT look better than it actually is.  Also, each study told the patients to apply the keratolytic 
at home.  Because of this, there is no way to measure if patients actually complied with this 
treatment plan and these studies had to solely rely on patients being truthful.  Also, a worst-case-
analysis was not completed at the end of the studies to account for patients which may have 
affected the significance of the findings.    Another limitation was pain.  Pain was reported 
significantly higher in the ALA-PDT than the placebo-PDT immediately after treatment so 
blinding may have been compromised for both subjects and investigators.  Also, all patients were 
referred from dermatology practices, which could make these patients more compliant than the 
general population when it comes to treatment of their recalcitrant warts. 
 There were also specific limitations to the study by Wang and co-authors.  In this study, 
there was a very small sample size making it very difficult to apply this data to the general 
population.  Also, this study solely focused on an Asian population.  This makes it unknown if 
the Asian population experiences a different response rate or has different complications than 
other populations of individuals.  It also makes it unknown if the results in this study can be 
generalized to different populations.  Also the p-value reported in the study was p=0.34, which 
questions the statistical significance and validity of the study. 
 A limitation in the Stender, Lock-Anderson and co-authors study was there was no 
exclusion criteria for the population they choose to be a part of their study.  This makes it hard to 
generalize the results to similar patients because the demographics of the patients in the study 
were not all given.  Another limitation in this study was the at home use of a keratolytic was 
optional.  The study never accounted for which patients chose and which patients chose not to 
apply the keratolytic.  3 patients were immunocompromised making the results unable to be 
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generalized to an entire population.  Also, the trial was not blinded after 4-6 weeks.  This gave 
both investigators and participants in the trial opportunity to skew the results.  Control group had 
no topical cream application which could have made the study unblinded earlier than the 
researches anticipated.    
CONCLUSION 
 Photodynamic therapy with topical 5-ALA is an effective treatment for adults with 
recalcitrant hand and foot warts.  While all 3 studies demonstrated a significant reduction in the 
number of recalcitrant hand and foot warts2,3,4, further research is needed to apply the results to 
the general population.  In future studies stricter inclusion criteria should be set for patients who 
failed a specific common treatment (e.g. cryotherapy), so practitioners know when to initiate 5-
ALA with PDT.  Also, only one study mentioned the different light sources available for 
photodynamic therapy, but only W3 was mentioned in this paper.3  Further studies are needed to 
compare the light sources available so a conclusion can be made about which is more effective in 
the treatment of recalcitrant warts.  Further studies are also needed to aim for FDA and insurance 
approval.  This would make practitioners and patients more willing to try this treatment option 
because cost and safety concerns would not be an issue   The reviewed studies show promise in 
the start of the research for treating recalcitrant hand and foot warts with 5-ALA and PDT. 
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